Market Signal Briefing

By

Katherine Li

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Benoit Tessier/REUTERS

2025-12-02T00:47:40.168Z

Costco filed a lawsuit to recover tariff payments imposed by the Trump administration.
The retailer challenged tariffs enacted under the International Emergency Economic Powers Act.
Costco is seeking a full refund of duties paid.

Costco is suing the government to recover tariff money.

The wholesale retailer has filed a lawsuit against the United States, the US Customs and Border Protection agency, and Rodney S. Scott, the Commissioner of US Customs and Border Protection.

The suit asks the US Court of International Trade to strike down tariffs imposed by President Donald Trump by executive order under the International Emergency Economic Powers Act.

In a complaint submitted Friday, November 28, the retailer said it is seeking a "full refund" of duties it paid after Trump used the emergency-powers law to levy what he described as "reciprocal" tariffs.

The complaint cited a previous lawsuit, VOS Selections, Inc. vs. Trump, filed against the Trump administration, for which the US Supreme Court heard arguments in early November.

"This separate action is necessary, however, because even if the IEEPA duties and underlying executive orders are held unlawful by the Supreme Court, importers that have paid IEEPA duties, including Plaintiff, are not guaranteed a refund for those unlawfully collected tariffs in the absence of their own judgment and judicial relief," the complaint reads.

Costco, the White House, and the US Customs and Border Protection agency did not immediately respond to requests for comment.

This is a developing story. Check back for updates.

Tariff

Read next

By

PYMNTS
 | 
December 1, 2025

 | 

Apple moved Monday to reset its artificial intelligence (AI) leadership, announcing that longtime machine learning chief John Giannandrea will step down and that Amar Subramanya will become vice president of AI. The shake-up comes as Apple races to shore up its Apple Intelligence roadmap and Siri’s AI makeover after a year of delays, glitches and senior departures that underscored how far it still trails leading AI rivals.

Apple said Giannandrea will shift into an advisory role before retiring in spring 2026. Subramanya will report to software chief Craig Federighi and oversee Apple Foundation Models, machine learning research and AI safety and evaluation, while the rest of Giannandrea’s organization moves under operations head Sabih Khan and services leader Eddy Cue.

Subramanya is a former Microsoft AI leader and longtime Google engineer who helped build the Gemini Assistant. Apple said his track record turning research into products will be central to future Apple Intelligence capabilities and a more personalized Siri expected next year.

“AI has long been central to Apple’s strategy, and we are pleased to welcome Amar to Craig’s leadership team,” Tim Cook said in the announcement.

The reshuffle underscores how urgently Apple is rebuilding its AI stack as generative AI becomes the operating system for consumer engagement, from shopping to payments and digital banking.

PYMNTS coverage over the past 18 months has cataloged the missteps this new team must fix. Apple delayed key Apple Intelligence features for iOS and iPadOS to avoid shipping unstable code. Early releases drew criticism for inaccurate AI-generated news alerts and message summaries, prompting Apple to pull the feature and sparking media warnings about the risk to information integrity.

Advertisement: Scroll to Continue

Engineering troubles have also slowed a next-generation Siri that is supposed to anchor Apple Intelligence and power new commerce and retail experiences, with reports of bugs, delays and internal reshuffles to fix the assistant. Most recently, PYMNTS reported that Apple is nearing a $1 billion-a-year deal to tap Google’s more powerful model to upgrade Siri — a stopgap while it races to close its capability gap in-house.

Taken together, those story lines make today’s elevation of Subramanya — and Federighi’s broader remit over Apple’s foundation models — a high-stakes bet that Apple can turn AI from a PR problem into a competitive weapon across its devices, services and payments ecosystem.

For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.

Sign up to receive our daily newsletter.

We’re always on the lookout for opportunities to partner with innovators and disruptors.

Learn More

PERTH, Australia--(BUSINESS WIRE)--Karlka Nyiyaparli Aboriginal Corporation (KNAC) Registered Native Title Body Corporate and Rio Tinto have signed an updated Native Title Agreement to strengthen ways of working together, deliver long-term benefits for the Nyiyaparli People and provide Rio Tinto with a clear framework for engaging on mine development on Nyiyaparli Country. The jointly developed agreement was guided by KNAC's Agreement Review Committee, supported by Common Law Holders, and infor.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection December 1, 2025 4:15 PM EST

Company Participants

Ted Karkus - Chairman & CEO

Presentation

Operator

Welcome, everyone. This is the ProPhase Labs Webinar. We'll be getting started in 3 minutes at a quarter after the hour. This is the ProPhase Labs Webinar with RedChip. We'll be started.

Ted Karkus
Chairman & CEO

Ted Karkus here, CEO of ProPhase Labs. How is that?

Operator

Thank you very much. Let us get started.

Hi. This is Craig with RedChip Companies. Thank you for joining today's event with ProPhase Labs, which trades on the NASDAQ under the ticker PRPH. With us today, we have Ted Karkus, the Chairman and CEO of ProPhase. We will begin with a brief presentation in a moment, and then we will answer your questions. [Operator Instructions] Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact should also be considered forward-looking statements. Of course, forward-looking statements involve risks and uncertainties. I now turn this webinar over to Ted. Please go ahead.

Ted Karkus
Chairman & CEO

Great. Thank you, Craig, and thank you all for joining. I am going to assume that most of you are new to the story of ProPhase Labs and to me, that's the approach I'm going. I do other presentations throughout the year usually monthly, where it's mostly for shareholders that know the company well. But the approach I'm going to take today is going to be

Recommended For You

Whale activity surrounding DOGE has fallen to its lowest level in the last 60 days, even as the token shows signs of a short-term bounce.This unexpected drop in large transactions is raising questions about the strength of the move and puts the Dogecoin price prediction under fresh scrutiny.

Bitcoin (BTC) attempted to close above a key resistance zone last week after briefly spiking to roughly $93,300. However, BTC failed to stop a mean-reversion trend, with the price dropping below $85,000 on Monday. 

Bitcoin four-hour chart. Source: Cointelegraph/TradingViewKey takeaways:

Bitcoin’s inability to close above $93,000 invalidated the confirmation of a bullish trend reversal.

Without fresh spot demand, Bitcoin could range between $80,600 and $96,000 until one of those levels is retested.

Lack of spot buyers flattens bullish sentimentThin spot liquidity and weak order-book depth are the major culprits in the current difficulty BTC encounters when attempting to move above $93,000. Although a dense cost-basis cluster sits around $84,000, more than 400,000 BTC acquired in this range have effectively formed an onchain floor.

Despite strong historical accumulation, active buying pressure between $84,000 and $90,000 has been absent. Meanwhile, many short-term holders remain underwater relative to their average entry of $104,600, putting the market in a low-liquidity zone.

Data from CryptoQuant showed that the Binance “Bitcoin to Stablecoin Reserve Ratio” has dropped to its lowest level since 2018. This implied an unprecedented build-up of stablecoins ready to buy BTC. Historically, such extreme stablecoin-to-BTC ratios on exchanges have preceded major rallies.

Binance Bitcoin/Stablecoin Reserve Ratio. Source: CryptoQuant/XWhile spot demand remains weak, the stablecoin overhang suggests the buying power to fuel a surge is on hand, but currently sitting idle.

Bitcoin may remain sideways ahead of the next FOMCBitcoin is now trapped between $96,000 (the top of the recent range) and $80,600–$84,000 (onchain cost-basis floor). Liquidity clusters remained on either side, which means a breakout in either direction could trigger sharp moves.

Bitcoin one-day analysis. Source: Cointelegraph/TradingViewFrom a bullish standpoint, a re-test of the lower band near $80,600–$84,000 might be constructive. That would allow BTC to soak up liquidity on the downside, rebuilding a base before a rebound.

Conversely, an immediate retest of $93,000–$96,000 without first gathering liquidity below could backfire as sellers may re-enter, risking further correction in line with the broader downtrend.

Liquidity remains on either side of the range for BTC. Source: Hyblock CapitalGiven the current backdrop, a period of sideways consolidation is increasingly likely ahead of the upcoming Federal Reserve (FOMC) meeting on Dec. 9–10. With markets watching for signals on US interest-rate policy, traders could remain sidelined rather than chase volatile moves. 

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

Journalist

Posted: December 2, 2025

XRP slipped more than 6% to trade near $2.02 on 1 December, as new on-chain data showed a major shift in whale behavior that appears to be weighing directly on price. 

Large holders controlling between 1 million and infinity XRP offloaded a significant portion of their supply this week, ending one of the longest accumulation phases seen this year.

The drop in holdings aligns closely with a sharp intraday sell-off and comes at a time when XRP’s broader distribution trend has already been visible for months. 

Data from Santiment reveals that whale balances have declined from their November peak, with the latest leg down marking one of the steepest single-week reductions of 2025.

Whales accelerate XRP distribution after months of slow unwinding
The supply held by top XRP cohorts shows that after months of steady accumulation through mid-year, large wallets began distributing gradually from September, eventually accelerating in late November. 

Source: Santiment

This week’s sharp decline indicates more aggressive selling, reversing what had been a stabilizing phase following XRP’s summer peak.

Source: Santiment

On-chain data shows whale holdings dropped from above 70 billion XRP to roughly 57 billion in the most recent snapshot, representing a substantial release of tokens into the market.

Accumulation/Distribution line confirms sustained sell pressure
Supporting the on-chain picture, XRP’s Accumulation/Distribution (A/D) line has trended downward since August, reflecting sustained selling by informed participants even during short-lived price recoveries. 

The indicator now sits close to 8.14 billion, marking one of its lowest levels in months.

This divergence between whale selling and price consolidation hinted at weakness well before this week’s breakdown.

XRP deepens its downtrend
XRP’s price chart clearly shows the impact. After failing to break above the $2.30–$2.35 resistance zone last week, XRP slipped sharply, forming a lower high and continuing its broader downtrend that began in September.

Source: TradingView

The 6% daily drop brings XRP back toward the lower range of its multi-week channel, confirming that sellers remain in control.

Unless the asset can reclaim $2.20 followed by the $2.30 zone, the bias remains bearish in the near term.

What comes next for XRP?
The combination of whale distribution, weakening accumulation metrics, and technical breakdowns suggests that XRP may face continued pressure unless fresh demand emerges at lower levels.

A key area to watch is the psychological support around the $1.90 level. A rebound from that zone could stabilize the structure, while a break below it may open the path toward deeper corrections.

Final Thoughts

Whale cohorts reducing their XRP supply have added to sell pressure, confirming a broader distribution trend that began months ago.
With the A/D line weakening and price unable to reclaim key resistance, XRP remains vulnerable unless buyers step in at major support zones.

Cardano is entering a very important phase in its development, as its founding institutions are attempting to deliver the core infrastructure that every major blockchain already treats as standard. On Nov.

The crypto market saw a sharp downturn today, dragging major assets lower and pushing Pi Network’s price into the red. With liquidity thinning across several trading pairs, Pi faced stronger-than-normal reactions, briefly dropping nearly 10% before stabilizing at a key support zone. This decline places Pi in a sensitive technical region that now guides short-term price expectations, especially as traders shift their focus to the major token unlock scheduled for December.

This upcoming Pi unlock will introduce 190 million new tokens—worth roughly $43 million at current market value—and is expected to amplify supply pressure in the short term. With liquidity already low, fresh supply enters the market faster, increasing volatility and making Pi more vulnerable to sharp swings from relatively small orders. Although unlock cycles have been consistent since early 2025, this particular event is drawing greater attention due to weakening market sentiment.

Amid the uncertainty, Pi developers recently announced a partnership with CiDi Games, aimed at expanding real-world utility for Pi through gaming. This initiative enables players to use Pi tokens within CiDi’s titles, reinforcing the network’s broader ecosystem goals. While the market remains under stress, the announcement helps soften concerns around the unlock and supports long-term growth narratives.

On the charts, Pi is testing a crucial break-or-hold zone. After falling below a rising channel in late November, the price retreated into a demand area that previously triggered rallies. If Pi stays above $0.2230, buyers may regain momentum and push toward $0.2306, with potential extension to $0.2476 if resistance thins. However, losing support could send Pi toward $0.2100, a historically reactive zone that shapes long-term outlooks.

With supply pressure and structural signals aligning, December becomes a decisive month for Pi Network’s price direction. A solid hold at current levels could spark recovery, while a breakdown may open the door to deeper declines.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Kalshi has taken a significant step in the prediction market space by launching fully tokenized event contracts on the Solana blockchain, positioning itself as a stronger rival to Polymarket. The move transforms Kalshi’s traditional event contracts into Solana-based tokens, enabling users to trade directly through blockchain wallets with greater speed, lower fees, and enhanced privacy. This shift also removes friction points such as account creation and verification checks, allowing broader access while preserving Kalshi’s federally regulated structure.

By leveraging Solana’s fast transaction speeds and low-cost infrastructure, Kalshi aims to support the high-volume activity required in event-based trading. Industry growth has been rapid, with prediction market volumes reaching nearly $28 billion through October, and weekly trading hitting new highs as interest in political, economic, and cultural forecasting increases. As activity rises, so does the need for deeper liquidity to maintain accurate pricing across Kalshi’s more than 3,500 listed markets.

To strengthen institutional access, decentralized finance protocols like DFlow and Jupiter will integrate with Kalshi by connecting their systems to the platform’s off-chain orderbook. This creates a bridge between Kalshi’s regulated trading environment and Solana’s open liquidity, offering users tighter spreads and more responsive pricing. Kalshi’s leadership notes that crypto-native traders are a key driver of liquidity and growth, making on-chain expansion essential for scaling the platform’s long-term roadmap.

Although the company is currently facing a lawsuit alleging market manipulation, Kalshi maintains that tokenization will improve transparency, market efficiency, and competitiveness, especially against on-chain-native platforms like Polymarket. Looking ahead, Kalshi plans to bring tokenized markets to additional blockchains, expecting on-chain prediction trading to become a standard model across the industry.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Ethereum fell more than 10% in the past 24 hours, dropping below the critical $3,000 threshold and briefly breaking support at $2,900. This sharp decline triggered widespread stop-loss orders and contributed to over $500 million in liquidated long positions. Trading volume surged to 33.2 billion—an increase of more than 200%—as market volatility intensified. The broader crypto market also suffered, sliding nearly 7% within a day and losing 20% over the past month. Major assets like Bitcoin, Solana, XRP, and Dogecoin mirrored this downward trend, collectively wiping out an estimated $200 billion in market value in just hours.

Despite the downturn, Ethereum reached a major technical milestone with the successful activation of its Fusaka upgrade on December 3. As the network’s second major upgrade of 2025, Fusaka synchronizes execution-layer and consensus-layer changes while enhancing Ethereum's ability to support higher Layer-2 throughput. In contrast to the market sell-off, BitMine Immersion Technologies continued expanding its ETH holdings, accumulating more than 96,798 ETH even as many firms reduced exposure during the decline.

Ethereum is currently trading around $2,738, reflecting strong bearish sentiment. Technical indicators reinforce this outlook: the MACD shows negative divergence with a red histogram, suggesting downward momentum may persist. The RSI has fallen to 32, placing ETH firmly in oversold territory and hinting at a potential reversal should buying pressure re-emerge.

Key price levels to monitor include support at $2,700 and $2,500. Failure to hold these zones could deepen the bearish trend, while a rebound from these levels may allow Ethereum to retest $2,900 and potentially reclaim $3,000. A move above $2,900 would signal early bullish recovery, whereas a drop under $2,500 could open the door to further losses.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Vanguard's platform services more than "50 million brokerage customers" who manage "over $11 trillion," Bloomberg said.

On December 1, XRP experienced a notable drop in its market value as several large-scale holders, often referred to as “whales,” opted to sell off a substantial portion of their holdings. This large-scale selling was not entirely unexpected, as on-chain data had been indicating a trend of increased distribution among these major institutional and private investors.

In brief
YZI Labs filed a consent statement with the SEC seeking major changes to management and the board at BNB treasury firm, CEA Industries.
The filing asks other BNC shareholders to vote on four separate proposals, including those that would expand the board at CEA and potentially elect YZi Labs' nominees.
Shares of CEA Industries (BNC) have fallen 92% from its yearly high set shortly after its treasury was established in July.
Binance co-founder Changpeng “CZ” Zhao and his investment firm, YZi Labs, filed a consent statement with the SEC that seeks crucial changes to the board and management team at publicly traded BNB treasury firm, CEA Industries (BNC). 

In a plea to BNC shareholders, the consent statement urges support for proposals to expand the board of directors, elect YZi Labs’ nominees, and repeal any provisions to the company’s bylaws not in effect when they were filed in July. 

“We believe the current board is in critical need of additional directors with the knowledge and experience to effectively oversee management, address the company’s stock price underperformance and operational issues, and restore investors’ faith in the company,” the filing reads.

Dear our valued community,

YZi Labs filed a Preliminary Consent Statement to expand the board of CEA Industries Inc. (BNC).

As a long-term partner to the investors in our network, we believe strong governance, transparent communication, and experienced oversight are essential… https://t.co/GrZyeETiUH

— YZi Labs (@yzilabs) November 27, 2025

“The stockholders of BNC deserve a well-functioning board that understands its role as a steward of stockholder resources,” it continues. “We are therefore launching this consent solicitation because we believe that stockholders must act now to prevent the further destruction of shareholder value.”

Intended for all shareholders of BNC, the filing contains a white consent card in which shareholders can consent, deny support, or abstain from providing a response. 

YZi Labs, which holds around 2.1 million shares of BNC or around 5% of the outstanding shares valued around $14 million as of Monday, contributed to the treasury firm’s $500 million PIPE earlier this summer, because it “recognized the institutional potential of a publicly listed BNB treasury vehicle.”

But less than a month after the treasury plan was unveiled, representatives for YZI Labs began contacting board-appointed director Hans Thomas to express concerns about the timeliness of investor updates and the firm’s lack of media presence, according to the filing. 

Concerns for YZi Labs continued to mount leading up to the filing, with more than a dozen reported contact attempts listed in the filing, including one in which representatives expressed concerns to CEA Industries CEO David Namdar about the time and attention he was granting to the treasury firm.

YZi Labs alleged in the filing that Namdar and others were actively involved in fundraising calls to promote another digital asset treasury, despite their positions at BNC. After concerns were expressed in September, YZi Labs purportedly learned that Namdar and Thomas were “promoting and seeking funding for other DATs” again in November. 

For those reasons and others outlined, YZi Labs maintains that company management is “directly responsible” for the poor performance of the BNB treasury firm. 

“Despite its advantageous market position and strong fundamentals, BNC has significantly underperformed on several levels,” the filing reads. “Since the closing of the PIPE, the company’s share price has significantly underperformed, despite the fact that the value of BNB, the primary asset of the company’s digital asset treasury, has increased over the same time period.”

Shares of BNC, which previously traded under the ticker VAPE, popped as high as $82.88 in July after the treasury announcement. Since that time, shares have fallen more than 92%, with BNC changing hands at $6.47 to finish the day. It fell 10% on Monday.

That’s despite the fact that BNB, the underlying treasury asset, set a new all-time high mark of $1,369 in October. However, it has fallen by nearly 40% to change hands at $829 as the broader market has fallen—but it’s still outperforming shares of BNC. 

If the firm wants to turn around its performance, YZi Labs said, then it needs to act now.

“We believe that time is of the essence. Stockholders cannot afford the leadership of the current board and management team,” the filing says. “We urge all BNC stockholders to act now to expand the size of the board and add experienced, competent directors to effectively oversee management [and] address the company’s stock price underperformance and operational issues, in order to maximize value for all stockholders—the true owners of BNC.” 

The names of the board member nominees YZi Labs hopes to appoint are redacted in the filing, and a representative for the firm did not immediately respond to Decrypt’s request for comment. Representatives for CEA Industries also did not immediately respond to Decrypt’s request for comment.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Long-term holders are scaling back their exposure to limit further losses – Cardano Price Predictions might not be in for a reversal just yet.

Similar to major assets in the cryptosphere, Dogecoin (DOGE) is facing renewed selling pressure as broader crypto market weakness intensifies, pushing the memecoin below several key technical levels.

Related Reading: $300 Million Crypto Bet: Kazakhstan’s Central Bank Gears Up

The decline occurs amid outflows, a weakening market structure, and fading speculative interest, raising questions about whether a deeper correction may be underway.

DOGE's price trends to the downside on the daily chart. Source: DOGEUSD on Tradingview
Dogecoin Breaks Key Supports as Selling Pressure Mounts
Dogecoin slipped below important support areas after breaking a bullish trend line on the hourly chart, continuing a multi-day downtrend. The price now trades below the 100-hour simple moving average, near $0.13, with MACD momentum strengthening in the bearish zone and the RSI remaining below 50.

The coin declined more than 8% in 24 hours, falling through multiple Fibonacci retracement zones and failing to regain footing above the 23.6% level of the latest swing move.

Analysts note that immediate resistance lies near the 50% retracement of the recent decline. A close above that threshold is needed to ease short-term downside pressure.

Failure to break above these resistance areas has kept momentum tilted toward sellers, with a retest of recent lows likely if the market does not stabilize.

Weak Flows and Derivatives Contraction Deepen Market Strain
Spot market flows show persistent distribution. Recent data revealed a $5.7 million outflow, extending the multi-month trend of reduced accumulation from large holders. Earlier inflows that supported rallies toward $0.30 have given way to steady red prints, reflecting waning confidence among major players.

Derivatives markets reinforce the weakening structure. Open interest has dropped more than 9% as traders unwind positions rather than add exposure during declines.

Long-short ratios show a mild long bias, but price action has repeatedly invalidated those positions, triggering waves of long-side liquidations whenever DOGE attempts to rise above short-term moving averages.

These repeated failed rallies have kept Dogecoin locked beneath declining EMAs between $0.154 and $0.202, a structure analysts say remains firmly bearish.

DOGE ETF Disappointment and Market Rotation Add Further Pressure
Dogecoin’s recently launched ETFs have not provided support. Combined inflows from major issuers barely surpassed $2 million, far below expectations and significantly weaker than the debut flows seen in Bitcoin or Ethereum funds.

The soft demand has signaled limited institutional appetite for the memecoin, contributing to negative sentiment.

Related Reading: XRP Hit By Violent 59% Leverage Flush As Speculators Slam The Brakes

Meanwhile, market rotation is moving toward utility-focused assets and payment-driven networks. Declining volume and low whale activity suggest traders may be shifting away from meme assets in favor of projects showing faster adoption and real-world use cases.

Cover image from ChatGPT, DOGEUSD chart from Tradingview

The situation on the market is not getting better any time soon, as the new week began with a substantial price drop across multiple assets, which could indicate an aggravation of the current market situation.

Clearly bearish SHIBBecause the structure is still clearly bearish, the answer to the question of whether SHIB will finally stabilize at this point or continue to bleed is not clear. Every major moving average, the 50, 100 and 200, are stacked above price and pointing downward. Instead of a trend attempting to bottom out, that is the hallmark of a protracted downtrend. 

The present price range is between $0.0000082 and $0.0000080, which has previously served as a reaction level. Buyers are frequently entering this range — not because SHIB is doing well but rather because the market typically pauses following sharp protracted selling. The RSI is currently in the low-40s, which indicates that it is not oversold but is getting close to a potential momentum bounce. Nothing here, however, shouts "reversal."

HOT Stories

SHIB/USDT Chart by TradingViewThe volume on the most recent red candles increased, indicating that sellers have not run out of options yet. Additionally, the market is not interested in firmly defending SHIB, as evidenced by the decline over the last two weeks, which was clear, steady and devoid of any significant counterpush. The best-case scenario is a brief technical rebound toward the 50-day EMA if SHIB is able to stabilize at this level. 

Since SHIB has not been able to recover that line since mid-October, it would probably serve as hard resistance because it is located well above the spot price. Only the notion of short-term mean reversion lends credence to that speculative rebound. The more plausible scenario is that SHIB either grinds lower or retests the recent lows after trading sideways for a while and failing to produce significant buying pressure. 

The chart shows no obvious bullish catalyst, no significant volume increase and no structural change. Therefore, anticipating a complete reversal is premature, even though the asset may pause at this point. Instead of viewing this area as a confirmed bottom, investors should view it as a possible resting place.

XRP barely thereThe candles on XRP’s chart indicate that the asset is barely hanging on inside its descending channel, and that the market is testing that lower boundary once more. XRP is situated on a structurally vulnerable section of its chart.

The initial touch of a channel bottom typically indicates seller fatigue and a possible relief bounce. However, a price return this fast on a second try typically indicates the opposite: buyers are not demonstrating enough dedication to defend support, and sellers are still in charge.

That weakness is validated by the price action. The most recent daily candle for XRP sliced downward with increasing volume, destroying earlier attempts to recover the mid-channel area around $2.20-$2.25. RSI is moving back toward the low 40s, indicating that the market is not oversold enough to trigger an automatic mean reversion. Momentum indicators are currently in a bearish zone.

You Might Also Like

The 50, 100 and 200 EMAs are all stacked above price and sloping downward, which is a classic downtrend structure rather than the start of a recovery, according to the moving averages. Therefore, the question is whether it matters at all to fall below the descending channel.

In actuality, it does, but not in a way that significantly alters the trend. The market has been indicating for weeks that XRP has not established a base, has not produced bullish volume and has not refuted the larger bearish structure. A clear break below the lower band would only confirm this.

The price would probably drop to new local lows between $1.95 and $2.00, possibly even lower if liquidity dried up. If XRP somehow manages to hold the line and stay inside the channel, the most investors should expect is another weak bounce toward the midrange. However, it would not be a reversal but rather a countertrend move. Buyers now bear the entire burden, and they have not yet shown up.

Ethereum takes another hitAt about $2,829, Ethereum recently printed a classic death cross on the daily chart, with the 50-day EMA falling below the 200-day EMA. By textbook standards, that is a bearish signal, suggesting trend exhaustion and the potential for deeper downside. However, ETH’s current structure is more complex than the term "death cross" suggests, and treating it as an inevitable catastrophe oversimplifies the situation.

First of all, the cross did not suddenly appear. Since the September breakdown, ETH has been in a persistent downward trend, with lower highs, lower lows and repeated failures to reach the 100-day EMA. The death cross is not the start of a bearish trend but rather its confirmation after weeks of activity. To put it another way, the harm was done well in advance of the averages crossing.

You Might Also Like

Second, look at the price reaction. ETH pulled back sharply but stayed above the November low, not collapsing on impact. This indicates that this was probably priced early by the market. In this case, a death cross is more of a lagging indicator, reflecting past weakness, than a catalyst for new selling. Normally, a death cross is most significant when it coincides with new downward momentum.

However, to completely ignore it would be naive. The unsuccessful attempt to recover $3,150 indicates that bulls are not powerful enough to regain momentum, and ETH continues to struggle beneath all significant moving averages. If the current support zone around $2,750-$2,800 gives way, ETH could easily slide toward $2,600, or even retest the $2,400 region where prior demand stepped in.

What matters now is whether ETH can form a higher low, something it has not achieved since early autumn. In the event that buyers intervene and the market stabilizes above $2,800, the death cross will no longer be as dire. If not, the cross might serve as a warning that the bearish structure is still in its early stages.

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors.

The investigation also examines whether Soleno’s public communications accurately reflected the commercial progress and safety profile of VYKAT™ XR following its regulatory approval.

In September 2025, after the FDA cleared VYKAT™ XR, Soleno highlighted to investors that the product rollout was performing strongly and surpassing internal expectations.

However, on Soleno’s November 4, 2025 third-quarter earnings call, the company discussed challenges that emerged during the launch period, noting a slowdown in new treatment initiations and an uptick in therapy discontinuations tied to non-serious adverse events. Management also acknowledged that the launch trajectory had been affected by external commentary published earlier in the year.

On August 15, 2025, short seller Scorpion Capital issued a report raising a number of concerns about VYKAT™ XR and Soleno’s commercialization plans. Among other assertions, the report questioned the safety profile of the drug, the sustainability of demand, and the concentration of early prescribing activity. Scorpion further criticized Soleno’s business model as being highly reliant on a single product with intellectual property protection expected to mature in the near term. The report additionally suggested that certain clinical research associated with the product warranted further scrutiny.

Following the release of the Scorpion report on August 15, 2025, Soleno’s stock price experienced significant volatility. Between August 14, 2025 and November 5, 2025, the Company’s share price declined by nearly 40%.

What if I purchased Soleno securities?
If you purchased SLNO securities and suffered losses, join our investigation now:
https://www.johnsonfistel.com/investigations/soleno-therapeutics-inc/

For more information, contact Jim Baker at [email protected] or (619) 814-4471. There is no cost or obligation to you.

About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who purchased on U.S. exchanges. For more information, please visit http://www.johnsonfistel.com.

Achievements
In 2024, Johnson Fistel was honored to be ranked among the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. The firm recovered approximately $90,725,000 for investors in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized among the top securities law firms in the United States.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471
[email protected] or [email protected]

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws.

What if I purchased Skye Bioscience securities?
If you purchased Skye Bioscience securities during the Class Period and suffered losses, you have until January 16, 2026 to seek appointment as lead plaintiff. Investors who suffered significant losses and would like to discuss their rights, or to determine whether they qualify to participate in any potential recovery, should visit: https://www.johnsonfistel.com/investigations/skye-bioscience/

You may also contact James Baker at (619) 814-4471 or [email protected], or Frank J. Johnson, Esq. at [email protected] to discuss your options privately.

What is this case about?
The Skye Bioscience class action lawsuit alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose that: (1) Skye’s drug candidate nimacimab was less effective than represented; (2) as a result, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) defendants’ public statements were therefore materially false and misleading.On October 3, 2025, when the true details entered the market, investors suffered substantial damages.

About Johnson Fistel, PLLP:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in securities class actions and shareholder derivative litigation, including international investors trading on U.S. exchanges. In 2024, the firm was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, recovering approximately $90.7 million for investors in cases where it served as lead or co-lead counsel.

Attorney Advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., 
(619) 814-4471 [email protected] or [email protected]

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on commercialization efforts and research initiatives to accelerate commercial adoption. Presentation.

December 01, 2025 5:52 PM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 1, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) that SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) that SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, Defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies.

On September 28, 2025, MoonLake announced week-16 results from its Phase 3 VELA program. The results showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX.

Following the announcement, MoonLake's stock price plummeted, falling $55.75 per share, or 89.9%, to close at $6.24 on September 29, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding MoonLake's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the MoonLake Immunotherapeutics class action, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276464

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

December 01, 2025 5:56 PM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Baxter between February 23, 2022 and July 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 1, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.

The true extent of Defendants' fraud was revealed on July 31, 2025, when the Company announced that it had decided to "voluntarily and temporarily pause shipments and planned installations of the Novum LVP" and that the Company was "unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs." On this news, Baxter stock dropped 22.4 percent, closing at $21.76 on July 31, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Baxter's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Baxter International class action, go to www.faruqilaw.com/BAX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276458

Analyst’s Disclosure:I/we have a beneficial long position in the shares of URBN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.